„”
Prion protein monoclonal antibody (PRN100) therapy for Creutzfeldt–Jakob disease: evaluation of a first-in-human treatment programme
The Lancet Neurology 2022
read onlineA high-content neuron imaging assay demonstrates inhibition of prion disease-associated neurotoxicity by an anti-prion protein antibody
Scientific Reports 2022
read onlinePrion neuropathology follows the accumulation of alternate prion protein isoforms after infective titre has peaked
Nature Communications 2014
read onlineIn vitro screen of prion disease susceptibility genes using the scrapie cell assay
Human Molecular Genetics 2014
read onlineGlobal microRNA level regulation of EGFR‐driven cell‐cycle protein network in breast cancer
Molecular Systems Biology 2012
read onlineMicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-κB and TGF-β signaling pathways
Oncogene 2012
read onlineAn identical, complex TP53 mutation arising independently in two unrelated families with diverse cancer profiles: the complexity of interpreting cancer risk in carriers
Oncogenesis 2012
read onlineInfrared-based protein detection arrays for quantitative proteomics
PROTEOMICS 2007
read onlineThe full-ORF clone resource of the German cDNA Consortium
BMC Genomics 2007
read onlineHigh-Throughput Flow Cytometry–Based Assay to Identify Apoptosis-Inducing Proteins
SLAS Discovery 2007
read onlineThe Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) is part of the Forschungsverbund Berlin e.V. (FVB), which legally represents seven non-university research institutes - members of the Leibniz Association - in Berlin.
Leibniz-Forschungsinstitut für Molekulare Pharmakologie im Forschungsverbund Berlin e.V. (FMP)
Campus Berlin-Buch
Robert-Roessle-Str. 10,
13125 Berlin, Germany